Projects per year
Personal profile
Area of Expertise
My laboratory is interested in developing and characterizing safe and effective drugs that can be used for the treatment of individuals afflicted with Parkinson’s disease, Alzheimer’s disease, schizophrenia, Tourette syndrome, and dystonia. We have also worked to develop drugs that can be used to assist in the rehabilitation of individuals who abuse cocaine. These studies have provided insights on the role of dopamine and sigma receptors in the brain.
Education/Academic qualification
BA in Chemistry, University of Illinois at Urbana-Champaign
BS in Microbiology, University of Illinois at Urbana-Champaign
PhD in Immunology, University of Pennsylvania
Fingerprint
Dive into the research topics where Robert Luedtke is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
UNTHSC Summer Research Internship Program (SRIP)
Jones, H., Luedtke, R. & Vishwanatha, J.
NIDA: National Institute on Drug Abuse
15/04/18 → 28/02/23
Project: Research
-
Discovery of functionally selective Alzheimer's disease therapeutics
Schetz, J., Luedtke, R., Luedtke, R. & SCHETZ, J.
15/09/17 → 31/05/19
Project: Research
-
Discovery of Functionally Selective Alzheimer's Disease Therapeutics
NIA: National Institute on Aging
15/09/17 → 31/05/22
Project: Research
-
Discovery of functionally selective Alzheimer's disease therapeutics
Luedtke, R., Schetz, J. & Luedtke, R.
15/09/17 → 31/05/22
Project: Research
-
Sigma 1 Receptor as a Target for Repetitive Concussive Brain Injury
Schreihofer, D., Luedtke, R. & Sumien, N.
1/08/16 → 30/04/18
Project: Research
-
Design and Synthesis of Conformationally Flexible Scaffold as Bitopic Ligands for Potent D3-Selective Antagonists
Kim, H. Y., Lee, J. Y., Hsieh, C. J., Taylor, M., Luedtke, R. R. & Mach, R. H., Jan 2023, In: International journal of molecular sciences. 24, 1, 432.Research output: Contribution to journal › Article › peer-review
Open Access -
Design, synthesis, and evaluation of functionalized 5-(4-arylpiperazin-1-yl)-N-arylpentanamides as selective dopamine D3 receptor ligands
Blass, B. E., Chen, P. J., Taylor, M., Griffin, S. A., Gordon, J. C. & Luedtke, R. R., Jan 2022, In: Medicinal Chemistry Research. 31, 1, p. 132-145 14 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Design, synthesis, and evaluation of functionalized 5-(4-arylpiperazin-1-yl)-N-quinolinyl-pentanamides as selective dopamine D3 receptor ligands
Blass, B. E., Chen, P. J., Taylor, M., Griffin, S. A., Gordon, J. C. & Luedtke, R. R., May 2022, In: Medicinal Chemistry Research. 31, 5, p. 749-761 13 p.Research output: Contribution to journal › Article › peer-review
-
Synthesis and evaluation of cyclic diamino benzamide based D3 receptor ligands
Blass, B. E., Chen, P. J., Taylor, M., Griffin, S. A., Gordon, J. C. & Luedtke, R. R., Mar 2022, In: Medicinal Chemistry Research. 31, 3, p. 446-461 16 p.Research output: Contribution to journal › Article › peer-review
-
Evaluation of substituted n-phenylpiperazine analogs as D3 vs. D2 dopamine receptor subtype selective ligands
Lee, B., Taylor, M., Griffin, S. A., McInnis, T., Sumien, N., Mach, R. H. & Luedtke, R. R., 1 Jun 2021, In: Molecules. 26, 11, 3182.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations